Nocturnal asthma uncontrolled by inhaled corticosteroids: Theophylline or long-acting β2 agonists?

Drugs

Volumn 61, Issue 3, 2001, Pages 391-418

  Holimon, T D ^a   Chafin, C C ^a   Self, T H ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BAMBUTEROL; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CIMETIDINE; CIPROFLOXACIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; ERYTHROMYCIN; FLUTICASONE PROPIONATE; FORMOTEROL; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; METHACHOLINE; NEDOCROMIL; PREDNISONE; RESPICUR; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; UNIPHYLLIN CONTINUS;

ASTHMA; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEART ATRIUM FIBRILLATION; HUMAN; INFLAMMATION; METERED DOSE INHALER; MORTALITY; NAUSEA; NIGHT; PATIENT EDUCATION; PATIENT MONITORING; QUALITY OF LIFE; REVIEW; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME;

EID: 0035064896     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161030-00007     Document Type: Review

References (139)

1. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate
2. Night-time asthma symptoms: No idle threat
3. Asthma: Analysis of sudden deaths and ventilatory arrests in hospital
4. Morbidity in nocturnal asthma: Sleep quality and daytime cognitive performance
5. Epidemiology of nocturnal asthma
6. Airways inflammation in nocturnal asthma
7. Cytokines in bronchoalveolar lavage fluid of patients with nocturnal asthma
8. Alveolar tissue inflammation in asthma
9. Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol
10. Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night
11. Plasma histamine, epinephrine, cortisol, and leukocyte beta-adrenergic receptors in nocturnal asthma
12. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma: Evidence that Gly16 correlates with the nocturnal phenotype
13. Influence of the parasympathetic and sympathetic nervous systems on nocturnal bronchial obstruction
14. Pathophysiology of nocturnal asthma
15. Nasal CPAP in non-apneic nocturnal asthma
16. Inhaled therapy reduces morning dips in asthma
17. A comparison of inhaled beclomethasone dipropionate and nedocromil sodium as additional therapy in asthma
18. The efficacy of high dose inhaled budesonide in replacing oral cortiocosteroid in Asian patients with chronic asthma
19. Use of inhaled corticosteroids in patients with mild asthma
20. Comparison of a beta2 agonist, terbutaline, with an inhaled corticosteroid budesonide, in newly detected asthma
21. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma
22. The effect of fluticasone propionate on functional status and sleep in children with asthma and on the quality of life of their parents
23. Efficacy of safety of budesonide inhalation suspension (pulmicort respules) in young children with inhaled steroid-dependent, persistent asthma
24. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma
25. Sustained release theophylline in nocturnal asthma
26. A once daily theophylline preparation in prevention of nocturnal symptoms in childhood asthma
27. Nocturnal wheezing in children: Management with controlled-release aminophylline
28. Controlled-release theophylline in the treatment of nocturnal asthma
29. Once-daily evening theophylline in nocturnal asthma patients on inhaled steroid and b-agonist
30. Theophylline: Potential antiinflammatory effects in nocturnal asthma
31. Controlled-release theophylline inhibits early morning airway obstruction and hyperresponsiveness in asthmatic subjects
32. The effect of sustained-release theophylline in nocturnal asthma
33. An evaluative study of the short-term effects of once-daily, sustained-release theophylline on sleep in nocturnal asthmatics
34. Efficacy of uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids
35. Multicenter comparison of once-daily uniphyl tablets administered in the morning or evening with baseline twice-daily theophylline therapy in patients with nocturnal asthma
36. Salmeterol: A four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease
37. A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: A Canadian multicenter study
38. Nocturnal asthma: Effect of salmeterol on quality of life and clinical outcomes
39. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma
40. Salmeterol in two different doses in the treatment of nocturnal bronchial asthma poorly controlled by other therapies
41. Salmeterol decreases nocturnal symptoms and β-agonist use in nocturnal asthma without altering airway inflammation
42. Effects of salmeterol on nocturnal asthma
43. Salmeterol in nocturnal asthma: A double blind, placebo controlled trial of a long acting inhaled β2 agonist
44. A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma
45. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma
46. A twelve month comparison of salmeterol with salbutamol in asthmatic patients: European Study Group
47. Long-term safety and efficacy of salmeterol in nocturnal asthmatics
48. Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids
49. Addition of inhaled salmeterol to inhaled corticosteroids in patients with poorly controlled nocturnal asthma
50. Efficacy of salmeterol xinafoate powder in children with chronic persistent asthma
51. Formoterol in the treatment of nocturnal asthma
52. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma
53. Effect of formoterol powder on nocturnal wheezes
54. Safety of formoterol administered over 20 months in 68 severe asthmatics
55. Formoterol dry powder capsules for inhalation in children with asthma treated over one year
56. Formoterol and terbutaline aerosols in nocturnal asthma
57. A 3-month comparison of formoterol with terbutaline via turbuhaler: A placebo-controlled study
58. Low-dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.)
59. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: A randomized controlled trial
60. Use of formoterol dry powder administered for three months via a single-dose inhaler in 1,380 asthmatic patients
61. Bambuterol in the treatment of asthma: A placebo-controlled comparison of once-daily morning vs evening administration
62. Bambuterol: Effective in nocturnal asthma
63. Nocturnal asthma: Effect of treatment with oral sustained-release terbutaline, inhaled budesonide, and the two in combination
64. Terbutaline sustained-release tablets in nocturnal asthma: A placebo-controlled comparison between a high and a low evening dose
65. Nocturnal asthma: Effects of slow-releae terbutaline on spirometry and arterial blood-gases
66. Effect of sustained release terbutaline on symptoms and sleep quality in patients with nocturnal asthma
67. Sustained-release terbutaline in nocturnal asthma
68. The effect of repeat action albuterol sulfate (proventil repetabs) in nocturnal symptoms of asthma
69. Treatment of nocturnal asthma with pulsed-release albuterol
70. Effect of controlled release salbutamol on nocturnal cough in asthma
71. A double-blind comparison of inhaled budesonide, long-acting theophylline, and their combination in treatment of nocturnal asthma
72. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma
73. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma
74. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma
75. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
76. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: A randomized clinical trial
77. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma
78. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma
79. Effect of long term treatment with salmeterol on asthma control: A double blind, randomized crossover study
80. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
81. Salmeterol versus theophylline in the treatment of asthma
82. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease
83. Salmeterol vs theophylline: Sleep and efficacy outcomes in patients with nocturnal asthma
84. Inhaled salmeterol or oral theophylline in nocturnal asthma?
85. Sustained-release theophylline and salmeterol in the management of nocturnal asthma: A comparison of effects on sleep quality and oxygenation
86. Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: A multicentre trial
87. Long-term, double-blind comparison of controlled release albuterol versus sustained-release theophylline in adolescents and adults with asthma
88. Once-daily theophylline in the treatment of nocturnal asthma
89. Nocturnal asthma: Slow-release terbutaline versus slow-release theophylline therapy
90. Salmeterol compared with slow-release terbutaline in nocturnal asthma: A multicenter, randomized, double-blind, double-dummy, sequential clinical trial
91. Comparative study of extended release albuterol sulfate and long-acting inhaled salmeterol xinafoate in the treatment of nocturnal asthma
92. A comparison of two long-acting beta-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms: The French Bambuterol Study Group
93. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids
94. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action
95. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease
96. Comparison of the efficacy, tolerability and patients acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma
97. Effect of disease states on theophylline serum concentrations: Are we still vigilant?
98. Revised FDA labeling guidelines for theophylline oral dosage forms
99. Theophylline toxicity: Clinical features of 116 consecutive cases
100. The arrhythmogenicity of theophylline: A multivariate analysis of clinical determinants
101. Predictors of major toxicity after theophylline overdose
102. Life-threatening events after theophylline overdose: A 10-year prospective analysis
103. Inpatient theophylline toxicity: Preventable factors
104. Are theophyllines being prescribed effectively and safely in general practice?
105. Current issues in the use of theophylline
106. Respiratory arrests in young asthmatics on salmeterol
107. Risks of salmeterol
108. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment
109. Salmeterol: A study by prescription-event monitoring in a UK cohort of 15 407 patients
110. 2-agonists in the treatment of asthma?
111. The efficacy and safety of inhaled salmeterol xinafoate (50mcg BD) compared with salbutamol (200mcg PRN) in children with asthma
112. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler
113. Incidence of acute decreases in peak expiratory flow following the use of metereddose inhalers in asthmatic patients
114. 2-agonists: Regular daily use of formoterol over five years
115. Inhaled salmeterol and salbutamol in asthmatic patients: An evaluation of asthma symptoms and the possible development of tachyphylaxis
116. Inhaled formoterol during one year in asthma: A comparison with salbutamol
117. Efficacy and tolerance of formoterol long-term treatment (12 months) in severe asthmatic patients
118. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma
119. An economic evaluation of asthma in the United States
120. The cost of asthma in New South Wales
121. Incidence and cost of hospital admissions secondary to drug interactions involving theophylline
122. Hospital admission for xanthine toxicity
123. Economic costs of theophylline toxicity
124. A scale for assessing quality of life in adult asthma sufferers
125. Evaluation of impairment of health-related quality of life in asthma: Development of a questionnaire for use in clinical trials
126. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life
127. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease
128. The response to salmeterol or theophylline in asthmatics either receiving or not-receiving inhaled corticosteroids
129. Quality of life in asthma clinical trials: Comparison of salmeterol and salbutamol
130. Regular bronchodilator therapy with salmeterol versus salbutamol in adult asthmatics: An efficacy and safety comparison
131. Asthma-specific quality of life in patients treated with salmeterol or albuterol
132. The impact of salmeterol versus albuterol on disease specific quality of life in mild to moderate asthmatics
133. The impact of salmeterol on asthma-specific quality of life in patients reporting nocturnal awakenings due to asthma [abstract]
134. 2-agonists: Formoterol and salmeterol